Skip to main content

Advertisement

SpringerLink
Log in

Hypersensitivity reactions from antineoplastic agents

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Antitumor drugs, like any other therapeutic agent, have the ability to incite hypersensitivity reactions. Certain of such drugs (e.g., L-asparaginase and taxol) cause reactions with great enough frequency to be a major impediment to repetitive use of the drug. Very few antitumor drugs have not had at least one reported instance of causing a hypersensitivity reaction. Most reactions are of the type I category in the Gell and Coombs classification, but there also are instances of types II, III, and IV reactions caused by many of the antineoplastic agents.

The mechanisms of such reactions have been poorly evaluated in many reports. In analyzing a hypersensitivity reaction in a patient being treated for cancer, one should document that the antitumor drug is indecd the offender, and not an ancillary drug or a formulation product that is being used. There are many tests that evaluate the source and mechanism of hypersensitivity reactions. This article reviews the current information on hypersensitivity reactions to antincoplastic drugs and provides a logical approach for their assessment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weiss RB, Bruno S: Hypersensitivity reaction to cancer chemotherapeutic agents. Ann Intern Med 94: 66–72, 1981

    Google Scholar 

  2. Weiss RB: Hypersensitivity reactions to cancer chemotherapy. In: Perry MC, Yarbro JW (eds) Toxicity of Chemotherapy. Grune and Stratton, Inc., Orlando, 1984, pp 101–123

    Google Scholar 

  3. Fvans WE, Tsiatis A, Rivera G, Murphy SB, Dahl GV, Denison M, Crom WR, Barker I.F, Mauer AM: Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 49: 1378–1383, 1982

    Google Scholar 

  4. Clavell LA, Gelber RA, Cohen HJ, Hitchocock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE: Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphocytic leukemia. N Engl J Med 315: 657–663. 1986

    Google Scholar 

  5. Rausen AR, Glidewell O, Holland JF, Ohnuma T, Sinks L, Freeman A, Cuttner J, Patterson RB, Falkson G, Kung FH, Levy RN: Superiority of I.-asparaginase combination chemotherapy in advanced acute lymphocytic leukemia of childhood. Randomized comparative trial of combination versus solo therapy. Cancer Clin Trials 1: 137–144, 1979

    Google Scholar 

  6. Nesbit M, Chard R, Evans A, Karon M, Hammond GD for the Children's Cancer Study Group: Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1: 9–13, 1979

    Google Scholar 

  7. Albo V, Miller D, Leiken S, Hammond D, Sather H: Toxicity experience with a second course of F. coli L-asparaginase (L-asp) therapy 3 years after induction course in children with acute lymphoblastic leukemia (ALL) in continuous remission (Abstr). Proc Am Soc Clin Oncol 2: 68, 1983

    Google Scholar 

  8. Khan A, Hill JM: Atopic hypersensitivity to L-asparaginase. Resistance to immunosuppression. Int Arch Allergy 40: 463–469, 1971

    Google Scholar 

  9. Fabry U, Korholz D, Jurgens H, Göbel U, Wahn V: Anaphylaxis to I.-asparaginase during treatment for acute lymphoblastic leukemia in children-evidence of a complement-mediated mechanism. Pediatr Res 19: 400–408, 1985

    Google Scholar 

  10. Kris MG, O'Connell JP, Gralla RJ, Wertheim MS, Parente RM, Schiff PB, Young CW: Phase I trial of taxol given as a 3-hour infusion very 21 days. Cancer Treat Rep 70: 605–607, 1986

    Google Scholar 

  11. Longnecker S, Donchower R, Grochow L, Cates A, Rice A, Colvin M, Ettinger D, Green L: Phase I and pharmacokinetic study of taxol in patients with advanced cancer (Abst) Proc Am Soc Clin Oncol 4: 32, 1985

    Google Scholar 

  12. Tutsch KD, Swaminathan S, Alberti D, Koeller J, Tormey DC, Bryan GT, Willson JKV, Trump DL: Phase I clinical trial with pharmacokinetic analysis of taxol (NSC 125973) given on a daily x5 schedule (Abstr) Proc Am Soc Clin Oncol 4: 40, 1985

    Google Scholar 

  13. Minutes of the Phase I Working Group. Biochemical Modulators Advisory Group, and Phase II meetings. Investigational Drug Branch. National Cancer Institute, Bethesda, March 20–21, 1985, pp 99–100

  14. Wiernik PH, Strauman JJ, Engel SL, Schwartz EL, Dutcher JP: Taxol (T) phase I and pharmacokinetic study (Abstr) Proc Am Soc Clin Oncol 5: 32, 1986

    Google Scholar 

  15. Criel AM, Hidajat M, Clarysse A, Verwilghen RL: Drug dependent red cell antibodies and intravascular haemolysis occurring in patients treated with 9 hydroxy-methyl-cllipticinium. Br J Haemtol 46: 549–556, 1980

    Google Scholar 

  16. Caillé P, Mondesir JM, Droz JP, Kerbat P, Goodman A, Ducret JP, Theodore C, Spielman M, Rouëssé J, Amiel JL: Phase II trial of clliptinium in advanced renal cell carcinoma. Cancer Treat Rep 69: 901–902, 1985

    Google Scholar 

  17. Doll DC, Weiss RB: Hemolytic anemia associated with antineoplastic agents. Cancer Treat Rep 69: 777–782, 1985

    Google Scholar 

  18. Mondesir J-M, Bidart J-M, Goodman A, Alberici GF, Caille P, Troalen F, Rouesse J, Bohuon C, Gralla RJ, Einzig AI, Buzdar AU: Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium acetate (NSC-264137) treatment: schedule dependency and relationship to hemolysis. J Clin Oncol 3: 735–740, 1985

    Google Scholar 

  19. Clarysse A, Brugarolas A, Siegenthaler P, Abele R, Cavalli F, DeJager R, Renard G, Rozencweig M, Hansen HH: Phase II study of 9-hydroxy-2N-methyl-ellipticinium acetate. Eur J Cancer Clin Oncol 20: 243–247, 1984

    Google Scholar 

  20. Pedinielli FJ, Routy JP, Blanc AP, Garrigues B: Accident mortel au cours d'un traitement par l'acétate d'elliptinium. Presse Med 14: 104, 1985

    Google Scholar 

  21. Grossman C, Cacoub P, Guillevin L, Royer I: Décés au cours d'un traitement par ellipticine. Ann Med Interne (Paris) 136: 519, 1985

    Google Scholar 

  22. Alberici GF, Fellous R, Bidart J-M, Troalen F, Mondesir J-M, Goodman A, Ho DH, Bohuon C: Human antibodies to the antineoplastic drug elliptinium: characterization and structure-activity relationships. J Allergy Clin Immunol 77: 624–630, 1986

    Google Scholar 

  23. O'Dwyer PJ, King SA, Fortner CL, Leyland-Jones B: Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol 4: 1262–1269, 1986

    Google Scholar 

  24. hayes FA, Abromowitch M, Green AA: Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies. Cancer Treat Rep 69: 439–441, 1985

    Google Scholar 

  25. O'Dwyer PJ, Weiss RB: Hypersensitivity reactions induced by etoposide. Cancer Treat Rep 68: 959–961, 1984

    Google Scholar 

  26. Tucci E, Pirtoli L: Etoposide-induced hypersensitivity reactions. Report of two cases. Chemioterapia 4: 460–462, 1985

    Google Scholar 

  27. Schell FC, Yap HY, Hortobagyi GN, Issell B, Esparza L: Phase II study of VP16–213 (etoposide) in refractory metastatic breast carcinoma. Cancer Chemother Pharmacol 7: 223–225, 1982

    Google Scholar 

  28. Garcia JM, Jimencz A: Chemotherapy combination with cyclophosphamide (CTX), adriamycin (ADM), vinrristine (VCR), and VP16–213 in small cell carcinoma of the lung (SCCL). Cancer Chemother Pharmacol 7: 199–201, 1982

    Google Scholar 

  29. Antman K, Pomfret E, Karp G, Skarin A, Canellos G: Phase II trial of ctoposide in previously treated small cell carcinoma of the lung. Cancer Treat Rep 68: 1413–1414, 1984

    Google Scholar 

  30. Sutherland CM, Loutfi A: Unusual reaction to VP-16–213 and avoidance by prolonged infusion. Cancer Treat Rep 66: 409, 1982

    Google Scholar 

  31. Habibi B, Lopez M, Serdaru M, Baumelou A, Vonlanthen M, Martcau R, Salmon C: Immune hemolytic anemia and renal failure due to teniposide. N Engl J Med 306: 1091–1093, 1982

    Google Scholar 

  32. Hunter D, Milton R, Perry KMA: Asthma caused by complex salts of platinum. Br J Ind Med 2: 92–98, 1945

    Google Scholar 

  33. Cleare MJ, Hughes EG, Jacoby B, Pepys J: Immediate (type I) allergic responses to platinum compounds. Clin Allergy 6: 183–195, 1976

    Google Scholar 

  34. Blumenreich MS, Needles B, Yagoda A, Sogani P, Grabstald H, Whitmore WF: Intravesical cisplatin for superficial bladder tumors. Cancer 50: 863–865, 1982

    Google Scholar 

  35. Denis L: Anaphylactic reactions to repeated intravesical instillation with cisplatin. Lancet 1: 1378–1379, 1983

    Google Scholar 

  36. Markman M: No increase in allergic reactions with intracavitary administration of cisplatin. Lancet 2: 1164, 1984

    Google Scholar 

  37. Khan A, Hill JM, Grater W, Loeb E, MacLellan A, Hill N: Atopic hypersensitivity to cis-dichlorodiammine-platinum (II) and other platinum complexes. Cancer Res 3: 2766–2770, 1975

    Google Scholar 

  38. Wiesenfeld M, Reinders E, Corder M, Yoo T-J, Dietz B, Lovett J: Successful re-treatment with cis-dichlordiammine-platinum (II) after apparent allergic reactions. Cancer Treat Rep 63: 219–221, 1979

    Google Scholar 

  39. Tachibana Y, Fukui I, Yokokawa M, Kasamatsu T, Horiuchi S, Higashi Y, Ishimaru H: Allergic reaction to CDDP: Report of 4 cases. Hinyokika Kiyo 30: 229–234, 1984

    Google Scholar 

  40. Lamb JD, Keogh JAM: Anaphylactoid reaction to mannitol. Can Anaesth Soc J 26: 435–436, 1979

    Google Scholar 

  41. Ackland SP, Hillcoat BL: Immediate hypersensitivity to mannitol: A potential cause of apparent hypersensitivity to cisplatin. Cancer Treat Rep 69: 562–563, 1985

    Google Scholar 

  42. Hall DJ, Diasio R, Goplerud DR: cis-Platinum in gynecologic cancer. III. Toxicity. Am J Obstet Gynecol 141: 309–312, 1981

    Google Scholar 

  43. Bacha DM, Caparros-Sison B, Allen JA, Walker R, Tan CTC: Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep 70: 865–869, 1986

    Google Scholar 

  44. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckman MJ, Harrap KR: Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9: 140–147, 1982

    Google Scholar 

  45. Bramwell VHC, Crowther D, O'Malley S, Swindell R, Johnson R, Cooper EH, Thatcher N, Howell A: Activity of JM9 in advanced ovarian cancer: A phase I-II trial. Cancer Treat Rep 69: 409–416, 1985

    Google Scholar 

  46. Creaven PJ, Madajewicz S, Pendyala L, Mittleman A, Pontes E, Spaulding M, Arbuck S, Solomon J: Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum (IV) (CHIP). Cancer Treat Rep 67: 795–800, 1983

    Google Scholar 

  47. Kelsen DP, Scher H, Alcock N, Leyland-Jones B, Donner A, Williams L, Greene G, Burchenal JH, Tan C, Philips FS, Young CW: Phase I clinical trial and pharmacokinetics of 4′-carboxyphthalato-(1,2-diaminocyclohexane) platinum (II) Cancer Res 42: 4831–4835, 1982

    Google Scholar 

  48. Scher HL, Kelsen D, Kalman L, Jones L, Burchenal J, Gralla R: Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small lung cancer. Cancer Chemother Pharmacol 12: 101–103, 1984

    Google Scholar 

  49. Brunner KW, Young CW: A methylhydrazine derivative in Hodgkins's disease and other malignant neoplasms. Ann Intern Med 63: 69–86, 1965

    Google Scholar 

  50. Glovsky MM, Braunwald J, Opelz G, Alenty A: Hypersensitivity to procarbazine associated with angioedema, urticaria, and low serum complement activity, J Allergy Clin Immunol 57: 134–140, 1976

    Google Scholar 

  51. Eyre HJ, Eltringham JR, Quagliana JM, Lane DM, Frank J, Vogel FS: Malignant glioma: A randomized trial of radiotherapy plus BCNU, procarbazine, or DTIC; a SWOG study (Abstr) Proc Am Soc Clin Oncol 1: 180, 1982

    Google Scholar 

  52. Eyre HJ, Eltringham JR, Gehan EA, Vogel FS, Al-Sarraf M, Talley RW, Costanzi JJ, Athens JW, Oishi N, Fletcher WS: Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: A Southwest Oncology Group study. Cancer Treat Rep 70: 1085–1090, 1986

    Google Scholar 

  53. Eyre HJ, Quagliana JM, Eltringham JR, Frank J, O'Bryan RM, McDonald B, Rivkin SE: Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. J Neuro-Oncol 1: 171–177, 1983

    Google Scholar 

  54. Lokich JJ, Moloney WC: Allergic reaction to procarbazine. Clin Pharmacol Ther 13: 573–574, 1972

    Google Scholar 

  55. Jones SE, Moore M, Blank N, Castellino RA: Hypersensitivity to procarbazine (Matulane) manifested by fever and pleuropulmonary reaction. Cancer 29: 498–500, 1972

    Google Scholar 

  56. Ecker MD, Jay B, Keohane MF: Procarbazine lung. Am J Roentgenol 131: 527–528, 1978

    Google Scholar 

  57. Lewis LD: Procarbazine associated alveolitis. Thorax 39: 206–207, 1984

    Google Scholar 

  58. Rassiga AL, Schwartz HJ, Forman WB, Crum ED: Cytarabine-induced anaphylaxis. Demonstration of antibody and successful desensitization. Arch Intern Med 140: 425–426, 1980

    Google Scholar 

  59. Castleberry RP, Crist WM, Holbrook T, Malluh A, Gaddy D: The cytosine arabinoside (Ara-C) syndrome. Med Pediatr Oncol 9: 257–264, 1981

    Google Scholar 

  60. Shah SS, Rybak ME, Griffin TW: The cytarabine syndrome in an adult. Cancer Treat Rep 67: 405–406, 1983

    Google Scholar 

  61. Markman M, Howell SB, King M, Pfeifle C, Wasserman SJ: Anaphylactic reaction to cytarabine: In vitro evidence that the response is immunoglobulin E mediated. Med Pediatr Oncol 12: 201–203, 1984

    Google Scholar 

  62. Manoharan A: The cytarabine syndrome in adults. Aust NZ J Med 15: 451–452, 1985

    Google Scholar 

  63. Ritch PS, Hansen RM, Heuer DK: Ocular toxicity from high-dose cytosine arabinoside. Cancer 51: 430–432, 1983

    Google Scholar 

  64. Burgdorf WH, Gilmore WA, Ganick RG: Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 97: 61–62, 1982

    Google Scholar 

  65. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes PC, Herzig GP: High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62: 361–369, 1983

    Google Scholar 

  66. Baer MR, King LE, Wolff SN: Palmar-plantar erythrodysesthesia and cytarabine. Ann Intern Med 102: 556, 1985

    Google Scholar 

  67. Peters WG, Willemze R: Palmar-plantar skin changes and cytarabine. Ann Intern Med 103: 805, 1985

    Google Scholar 

  68. Levine LE, Medenica MM, Lorincz AL, Soltani K, Raab B, Ma A: Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. Arch Dermatol 121: 102–104, 1985

    Google Scholar 

  69. Cordonnier C, Roujeau JC, Vernant JP, Matheron S, Ganem G: Cancer chemotherapy and acral erythema. Ann Intern Med 97: 783, 1982

    Google Scholar 

  70. Harriat TJ, Fine JD, Berman RS, Murphy GF, Mihm MC: Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Arch Dermatol 118: 263–266, 1982

    Google Scholar 

  71. Flynn TC, Harriat TJ, Murphy GF, Loss RW, Moschella SL: Neutrophilic eccrine hidradenitis: A distinctive rash associated with cytarabine therapy and acute leukemia. J Am Acad Dermatol 11: 584–590, 1984

    Google Scholar 

  72. Beutner KR, Packman CH, Markowitch W: Neutrophilic eccrine hidradenitis associated with Hodgkin's disease and chemotherapy. Arch Dermatol 122: 809–811, 1986

    Google Scholar 

  73. Stanton GF, Raymond V, Wittes RE, Schulman P, Budman D, Baratz R, Williams L, Petroni GR, Geller NL, Hancock C, Kreis W, Young CW: Phase I and clinical pharmacological evaluation of 4′-deoxydoxorubicin in patients with advanced cancer. Cancer Res 45: 1862–1868, 1985

    Google Scholar 

  74. Solimando DA, Wilson JP: Doxorubicin-induced hypersensitivity reactions. Drug Intell Clin Pharm 18: 808–811, 1984

    Google Scholar 

  75. Aulbert E, Schmidt CG: Anaphylaktische reaktion unter cyclophosphamid-infusion. Onkologie 6: 82–83, 1983

    Google Scholar 

  76. Kim KC, Kesarwala HH, Colvin M, Saidi P: Hypersensitivity reaction to a metabolite of cyclophosphamide. J Allergy Clin Immunol 76: 591–594, 1985

    Google Scholar 

  77. Lakin JD, Cahill RA: Generalized urticaria to cyclophosphamide: Type I hypersensitivity to an immunosuppressive agent. J Allergy Clin Immunol 58: 160–161, 1976

    Google Scholar 

  78. Rodriquez V, Cabanillas F, Bodey GP, Freireich EJ: Studies with ifosfamide in patients with malignant lymphoma. Semin Oncol 9 (suppl 1): 87–92, 1982

    Google Scholar 

  79. Case D, Ervin T, Gottlieb A, Anderson J: Phase II trial of ifosfamide and mesna in non-Hodgkin's lymphoma (Abstr) Proc Am Soc Clin Oncol 5: 189, 1986

    Google Scholar 

  80. Lang E, Goos M: Hypersensitivity to mesna. Lancet 2: 329, 1985

    Google Scholar 

  81. Cornwell GG, Pajak TF, McIntyre OR: Hypersensitivity reactions to iv melphalan during treatment of multiple myeloma: Cancer and Leukemia Group B experience. Cancer Treat Rep 63: 399–403, 1979

    Google Scholar 

  82. Cooper MR, McIntyre OR, Propert KJ, Kochwa S, Anderson K, Coleman M, Kyle RA, Prager D, Rafla S, Zimmer B: Single, sequential, and multiple alkylating agent therapy for multiple myeloma: A CALGB study. J Clin Oncol 4: 1331–1339, 1986

    Google Scholar 

  83. Bleichner F, Mende S: Allergische reaktion auf melphalan. Onkologie 5: 195, 1982

    Google Scholar 

  84. Woolley PV, Sacher RA, Priego VM, Schanfield MS, Bonnem F: Methotrexate-induced immune haemolytic anemia. Br J Haematol 54: 543–552, 1983

    Google Scholar 

  85. Marks CR, Wilkens RF, Wilske KR, Brown PB: Small-vessel vasculitis and methotrexate. Ann Intern Med 100: 916, 1984

    Google Scholar 

  86. daCosta M, Isacoff W, Rothenberg SP, Iqbal MP: Protein-methotrexate-IgG complexes in the serum of patients receiving high-dose antifolate therapy. Cancer 46: 471–474, 1980

    Google Scholar 

  87. Doyle LA, Berg C, Bottino G, Chabner B: Erythema and desquamation after high-dose methotrexate. Ann Intern Med 98: 611–612, 1983

    Google Scholar 

  88. Weiss RB, James WD, Major WB, Porter MB, Allegra CJ, Curt GA: Skin reactions induced by trimetrexate, an analog of methotrexate. Invest New Drugs 4: 159–163, 1986

    Google Scholar 

  89. Carter JJ, McLaughlin ML, Bern MM: Bleomycin-induced fatal hyperpyrexia. Am J Med 74: 523–525, 1983

    Google Scholar 

  90. Tropé C, Johnsson J-F, Larsson G, Simonsen E: Bleomycin alone or combined with mitomycin C in treatment of advanced or recurrent squamous cell carcinoma of the vulva. Cancer Treat Rep 64: 639–642, 1980

    Google Scholar 

  91. Khansur T, Little D, Tavassoli M: Fulminant and fatal angioedema caused by blcomycin treatment. Arch Intern Med 144: 2267, 1984

    Google Scholar 

  92. Perry DJ, Weiss RB, Hoth DF: Hypersensitivity reactions to amsacrine. Cancer Treat Rep 69: 199–201, 1985

    Google Scholar 

  93. Gassel W-D, Gropp C, Havemann K: Acute allergic reaction to vincristine sulfate. Oncology 41: 403–405, 1985

    Google Scholar 

  94. Østerlind K, Dombernowsky P, Sørensen PG, Hansen HH: Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma. Cancer Treat Rep 65: 245–248, 1981

    Google Scholar 

  95. Young JA, Howell SB, Green MA: Pharmacolinetics and toxicity of 5-day continuous infusion of vinblastine. Cancer Chemother Pharmacol 12: 43–45, 1985

    Google Scholar 

  96. DeBeer R, Kabakow B: Anaphylactoid reaction. Associated with intravenous administration of 5-fluorouracil. NY State J Med 79: 1750–1751, 1979

    Google Scholar 

  97. Sridhar KS: Allergic reaction to 5-fluorouracil infusion. Cancer 58: 862–864, 1986

    Google Scholar 

  98. Santos AM, Medina FS: Anaphylactic reaction following iv administration of 5-fluorouracil. Cancer Treat Rep 70: 1346, 1986

    Google Scholar 

  99. Lokick JJ, Moore C: Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101: 798–800, 1984

    Google Scholar 

  100. Feldman LD, Ajani JA: Fluorouracil-associated dermatitis of the hands and feet. JAMA 254: 3479, 1985

    Google Scholar 

  101. Atkins JN: Fluorouracil and the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 102: 419, 1985

    Google Scholar 

  102. Taylor WB, Cantwell BMJ, Roberts JT, Harris AL: Allergic reactions to mitoxantrone. Lancet 1: 1439, 1986

    Google Scholar 

  103. Anderson KC, Cohen GI, Garnick MB: Phase II trial of mitoxantrone. Cancer Treat Rep 66: 1929–1931, 1982

    Google Scholar 

  104. Koehn GG, Balizet LB: Unusual local cutaneous reaction to dacarbazine. Arch Dermatol 118: 1018–1019, 1982

    Google Scholar 

  105. Nissenkorn I, Herrod H, Soloway MS: Side effects associated with intravesical mitomycin C. J Urol 126: 596–597, 1981

    Google Scholar 

  106. Eifer K, Frentz G: Palmar erythema induced by mitomycin C. Ugeskr Laeger 148: 136–137 1986

    Google Scholar 

  107. Spencer HJ: Local erythema multiforme-like drug reaction following intravenous mitomycin C and 5-fluorouracil. J Surg Oncol 26: 47–50, 1984

    Google Scholar 

  108. Posada JG, O'Dwyer PJ, Hoth DF: Anaphylactic reactions to diaziquone. Cancer Treat Rep 68: 1215–1217, 1984

    Google Scholar 

  109. Wilson JP, Solimando DA, Edwards MS: Parenteral benzyl alcohol-induced hypersensitivity reaction. Drug Intell Clin Pharm 20: 689–691, 1986

    Google Scholar 

  110. Howrie DL, Ptachcinski RJ, Griffith BP, Hardesty RJ, Rosenthal JT, Burckart GJ, Venkataramanan R: Anaphylactoid reations associated with parenteral cyclosporine use: Possible role of Cremophor EL. Drug Intell Clin Pharm 19: 425–427, 1985

    Google Scholar 

  111. Dye D, Watkins J: Suspected anaphylactic reaction to Cremophor EL. Br Med J 280: 1353, 1980

    Google Scholar 

  112. VanArsdel PP: Drug allergy, an update. Med Clinics North Am 65: 1089–1103, 1981

    Google Scholar 

  113. Blumenthal MN, Yunis E, Mendell N, Elston RC: Preventive allergy: The genetics of IgE-mediated disease. J Allergy Clin Immunol 78: 968–973, 1986

    Google Scholar 

  114. Adkinson NF: Tests for immunological drug reactions. In: Rose NR, Friedman H, Fahey JL (eds) The Manual of Clinical Laboratory Immunology. American Society for Microbiology, Washington, DC, 1986, pp 692–696

    Google Scholar 

  115. Smith PL, Kagey-Sobotka A, Bleecker ER, Lichenstein L: Physiologic manifestations of human anaphylaxis. J Clin Invest 66: 1072–1079, 1980

    Google Scholar 

  116. Petz LD: Autoimmune and drug-induced immune hemolytic anemia. In: Rose NR, Friedman H, Fahey JL (eds) The Manual of Clinical Laboratory Immunology. American Society for Microbiology, Washington, DC, 1986, pp 613–630

    Google Scholar 

  117. Habibi B, Baumelou A, Serdaru M: Acute intravascular hemolysis and renal failure due to teniposide related antibody. Lancet 1: 1423–1424, 1981

    Google Scholar 

  118. Ruddy S: Complement. In: Rose NR, Friedman H, Fahey JJ, (eds) The Manual of Clinical Laboratory Immunology. American Society for Microbiology, Washington, DC, 1986, pp 175–185

    Google Scholar 

  119. Sams WM, Thorne EG, Small P, Mass MF, McIntosh RM, Stanford RE: Leukocytoclastic vasculitis, Arch Dermatol 112: 219–226, 1976

    Google Scholar 

  120. Seltzer SE, Griffin T, D'Orsi C, Tryka F, Herman PJ: Pulmonary reaction associated with neocarzinostatin therapy. Cancer Treat Rep 62: 1271–1272, 1978

    Google Scholar 

  121. Valenzuela R, Bergfeld WF, Deodhar SD: Interpretation of Immunofluorescent Patterns in Skin Diseases, American Society of Clinical Pathologists Press, Chicago, 1984

    Google Scholar 

  122. Kligman AM, Leyden JJ: Reactions to standard patch test materials. Acta Dermatovener 59: 101–103, 1979

    Google Scholar 

  123. Rocklin RE, David JR: Detection in vitro of cellular hypersensitivity to drugs. J Allergy Clin Immunol 48: 276–281, 1971

    Google Scholar 

  124. VanScott EJ, Kalmanson JD: Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard. Cancer 32: 18–30, 1973

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Medical Oncology, Walter Reed Army Medical Center, Washington, DC, USA

    Raymond B. Weiss & James R. Baker Jr.

  2. Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, DC, USA

    Raymond B. Weiss & James R. Baker Jr.

  3. Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

    Raymond B. Weiss & James R. Baker Jr.

Authors
  1. Raymond B. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James R. Baker Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weiss, R.B., Baker, J.R. Hypersensitivity reactions from antineoplastic agents. Cancer Metast Rev 6, 413–432 (1987). https://doi.org/10.1007/BF00144273

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00144273

Key words

Search

Navigation